Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about AMGN, unsubscribe in one click. Privacy
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Evolocumab FDA approved Aug 2015 · Repatha |
Coronary Artery Disease | Phase 4 · NCT07803679 | Not yet recruiting |
| Apremilast FDA approved Mar 2014 · Otezla |
Arthritis, Psoriatic | Phase 4 · NCT03747939 | Completed |
| Pegloticase FDA approved Sep 2010 · Krystexxa |
Gout | Phase 4 · NCT06229145 | Completed |
| Erenumab FDA approved May 2018 · Aimovig |
Migraine | Phase 3 · NCT03836040 | Active not recruiting |
| Romiplostim FDA approved Aug 2008 · Nplate |
Primary Immune Thrombocytopenia | Phase 3 · NCT07700238 | Recruiting |
| Sotorasib FDA approved May 2021 · Lumakras |
Non-Small Cell Lung Cancer (NSCLC) | Phase 3 · NCT05920356 | Recruiting |
| Tarlatamab FDA approved May 2024 · Imdelltra |
Small-cell Lung Cancer | Phase 3 · NCT07005128 | Active not recruiting |
| Blinatumomab FDA approved Dec 2014 · Blincyto |
Philadelphia Chromosome Negative B-cell Precursor | Phase 3 · NCT07223190 | Not yet recruiting |
| Denosumab FDA approved Jun 2010 · Prolia |
Lung Cancer Non-small Cell Stage IV | Phase 3 · NCT02129699 | Terminated |
| Carfilzomib FDA approved Jul 2012 · Kyprolis |
Multiple Myeloma | Phase 2 · NCT05789303 | Recruiting |
| Romosozumab FDA approved Apr 2019 · Evenity |
Healthy Participants | Phase 1 · NCT07811999 | Not yet recruiting |
| Routine Lipid Management | Coronary Artery Disease | Phase 4 · NCT07803679 | Not yet recruiting |
| HyperCVAD | Philadelphia Chromosome Negative B-cell Precursor | Phase 3 · NCT07223190 | Not yet recruiting |
| Maridebart Cafraglutide | Heart Failure With Preserved Ejection Fraction | Phase 3 · NCT07037459 | Recruiting |
| Predniso(lo)ne | Primary Immune Thrombocytopenia | Phase 3 · NCT07700238 | Recruiting |
| Tezepelumab | Chronic Obstructive Pulmonary Disease (COPD) | Phase 3 · NCT06883305 | Recruiting |
Also used in these trials (approved or third-party drugs, not AMGN's own candidates): Ivabradine, Avacopan, Methotrexate, Pembrolizumab, Nivolumab, Ocrelizumab, Etoposide, Abiraterone Acetate, Aflibercept, Cabazitaxel, Carboplatin, Durvalumab.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
AMGN holds $27.4B in cash and short-term investments (as of Jun 30, 2026) and its operations are currently cash-flow neutral or positive.
Dilution pressure: 0 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when AMGN files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Vanguard Capital Management | Institution (13G, 5%+) | 40,510,484 | 7.49% | 2026-03-31 |
| Capital World Investors | Institution (13G, 5%+) | 29,596,119 | 5.47% | 2026-03-31 |
| Robert A Bradway Chairman, CEO and President, Director · +79,176 options |
Insider | 655,220 | 0.12% | 2026-05-07 |
| Esteban Santos EVP, Operations |
Insider | 83,757 | 0.02% | 2026-05-07 |
| Murdo Gordon EVP, Global Commercial Ops · +23,752 options |
Insider | 51,222 | 0.01% | 2026-05-07 |
| Peter H. Griffith EVP & CFO · +23,752 options |
Insider | 50,150 | 0.01% | 2026-05-07 |
| David M Reese EVP & Chief Technology Officer · +19,002 options |
Insider | 42,256 | 0.01% | 2026-05-07 |
| Jonathan P Graham EVP & Gen. Counsel & Sec. · +17,022 options |
Insider | 39,712 | 0.01% | 2026-05-07 |
| James E. Bradner EVP, Research and Development · +21,773 options |
Insider | 30,016 | 0.01% | 2026-05-07 |
| Robert Eckert Director |
Insider | 26,251 | 0.00% | 2026-05-19 |
| Tyler Jacks Director |
Insider | 18,284 | 0.00% | 2026-05-19 |
| Thomas J.W. Dittrich EVP & CFO |
Insider | 16,860 | 0.00% | 2026-09-01 |
Share count 540,632,005 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for AMGN and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →